The rise of second-generation non-nucleoside reverse transcriptase inhibitors: Etravirine, rilpivirine, UK-453061 and RDEA-806

Drugs of the Future

Volumn 33, Issue 8, 2008, Pages 691-699

  Abdel Malak, Mark ^a   Gallati, Christine ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DAPIVIRINE; DARUNAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; MIV 150; NEVIRAPINE; NUCLEOTIDYLTRANSFERASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RDEA 806; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UK 453061; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER TOXICITY; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; PRURITUS; REVIEW; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VIRUS LOAD; WASTING SYNDROME;

EID: 59349111624     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.08.1206423     Document Type: Review

References (34)

1. Department of Health and Human Services. Pane on Antiretroviral Guidelines for Adult and Adolescents; Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available from: http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentsGL.pdf
2. Shafer, R.W., Smeaton, L.M., Robbins, G.K. et al. AIDS Clinical Trials Group 384 Team: Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003, 49(24): 2304-15.
3. MacArthur, R.D., Novak, R.M., Pen, G. et al. Long-term clinical and immunologic outcomes are similar in HIV-infected persons randomised to NNRTI vs. Pl vs. NNRT+Pl-based antiretroviral regimens as initial therapy: Results of NNRTI + the CPCRA 058 FIRST Study. 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst TUAB0102.
4. U.S. Food and Drug Administration. FDA approves new HIV drug after priority review. Available from: http://www.fda.gov/bbs/topics/NEWS/ 2008/NEW01783.html
5. Hui, D.Y. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003, 42(2): 81-92.
6. Staszewski, S., Morales-Ramirez, J., Tashima, K.T. et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults, Study 006 Team. N Engl J Med 1999, 341(25): 1865-73.
7. Vanni, T., Morejón, K.M., Santana, R.C. et al. Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil. Braz J Med Biol Res 2007, 40(7): 963-9.
8. Matthews, G.V., Sabin, C.A., Mandalia, S. et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: A cohort study. AIDS 2002, 16(1): 53-61.
9. Ridler, S.A., Haubrich, R., DiRienzo, G. et al. A prospective, randomised, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection, 16th Int AIDS Conf (Aug 13-18, Toronto) 2006, Abst THLB0204.
10. Bacheler, L., Jeffrey, S., Hanna, G. et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001, 75(11): 4999-5008.
11. Delaugerre, C., Rohban, R., Simon, A. et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001, 65(3): 445-8.
12. Bacheler, L.T., Anton, E.D., Kudish, P. et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000, 44(9): 2475-84.
13. Johnson, J.A., Li, J.F., Morris, L. et al. Emergence of drug-resistance HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005, 192(1): 16-23.
14. Leith, J., Piliero, P., Storfer, S., Mayers, D., Hinzmann, R. Appropriate use of nevirapine for long-term therapy. J Infect Dis 2005, 192(3): 545-6.
15. Temiz, N.A., Bahar, I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 2002, 49(1): 61-70.
16. De Bethune, M.P., Hertogs, K., Azijn, H. et al. R165335-TMC125, a third generation non nucleoside reverse transcriptase inhibitor (NNRTI), inhibits 98% of more than 2000 recombinant HIV clinical isolates at 100 nM. 40th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Toronto) 2000, Abst F-1841.
17. Andries, K., Azijn, H., Thielemans, T. et al. TMC1225, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48(12): 4680-6.
18. Das, K., Clark, A.D., Lewi, P.J. et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004, 47(10): 2550-60.
19. FDA approves INTELENCE(TM) (etravirine) for HIV combination therapy. Johnson & Johnson Press Release, January 18, 2008.
20. Gazzard, B., Pozniak, A., Rosenbaum, W. et al. An open-label assessment of TMC125 - A new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRT1 resistance. AIDS 2003, 17(18): F49-54.
21. Gruzdev, B., Rakhmanova, A., Doubovskaya, E. et al. A randomised, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve, HIV-1 infected subjects. AIDS 2003, 17(17): 2487-94.
22. Madruga, J., Cahn, P., Grinsztejn, B. et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-Week results froma randomised, double-blind, placebo-controlled trial. Lancet 2007, 370(9581): 29-38.
23. Lazzarin, A., Campbell, T., Clotet, B. et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2:24-Week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370(9581): 39-48.
24. Nadler, J.P., Berger, D.S., Blick, G. et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysis. AIDS 2007, 21(6): F1-10.
25. Woodfall, B., Vingerhoets, J., Peeters, M. et al. Impact of NNRTI and NPTI resistance on the response to the regimen of TMC125 plus two NRT/s in study TMC125-C227. 8th Int Congr Drug Ther HIV Infect (Nov 12-16, Glasgow) 2006, Abst PL5.6.
26. Guillemont, J., Pasquier, E., Palandjian, P. et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem 2005, 48(6): 2072-9.
27. Janssen, P.A., Lewi, P.J., Arnold, E. et al. In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4- 4-4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]- 2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005, 48(6): 1901-9.
28. Goebel, F., Yakovlev, A., Pozniak, A.L. et al. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS 2006, 20(13): 1721-6.
29. Pozniak, A., Morales-Ramirez, J., Mohapi, L. et al. 48-Week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naive patients. 14th Conf Retroviruses Opportunistic Infect (CROI) (Feb 25-28, Los Angeles) 2007, Abst 144LB. Available from: http://www.retroconterence.org/2007/Abstracts/30659.htm
30. Corbau, R., Allan, G., Burt, C. et al. UK-453,061: A non-nucleoside reverse transcriptase inhibitor for the treatment of drug-resistant HIV infections. 47th Intersci Cont Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst F1-945.
31. Davis, J., Jenkins, T., Asken, E., Stafford, H., Hackman, F., Weissgerber, G. Safety, toleration and pharmacokinetics of single and multiple oral doses of UK 453,061, a novel NNRTi, in healthy male subjects. 4th IAS Conf HIV Pathog Treat Prev (July 22-25, Sydney) 2007, Abst WEPEA 109.
32. Fätkenheuer, G., Staszewski, S., Plettenburg, A. et al. Shortterm monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV infected patients. 4th IAS Conf HIV Pathog Treat Prev (July 22-25, Sydney) 2007, Abst WESS202.
33. De La Rosa, M., Kim, H.W., Gunic, E. et al. Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2006, 16(17): 4444-9.
34. Hamatake, R., Zhang, Z., Xu, W., Bellows, D., Raney, A., Giradet, J.L., Quart, B. RDEA806, a potent NNRTI with a high genetic barrier to resistance. 47th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst 1662.